Immix Biopharma, Inc. announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site. NXC-201 will be manufactured for each individual patient using the patient?s own T cells at its cellular immunotherapy manufacturing facility in California.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | +6.82% | +4.91% | -66.04% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.04% | 58.09M | |
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-9.06% | 33.03B | |
+55.32% | 24.68B | |
-16.61% | 15.12B | |
-9.14% | 12.81B | |
-12.11% | 11.79B | |
-43.61% | 11.64B | |
+7.79% | 8.9B |
- Stock Market
- Equities
- IMMX Stock
- News Immix Biopharma, Inc.
- Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site